Results for tag: "Primary Sclerosing Cholangitis Drug"

Primary Sclerosing Cholangitis (PSC) is a chronic, progressive liver disease that affects the bile ducts. It is characterized by inflammation and scarring of the bile ducts, leading to obstruction of bile flow and eventual liver damage. Treatment for PSC is largely supportive, with the goal of managing symptoms and preventing complications. Drug therapy is used to reduce inflammation and improve bile flow. The PSC drug market is composed of a variety of medications, including immunosuppressants, antibiotics, and antifibrotic agents. Immunosuppressants are used to reduce inflammation and prevent further damage to the bile ducts. Antibiotics are used to treat infections that can occur due to bile duct obstruction. Antifibrotic agents are used to reduce scarring and improve bile flow. The PSC drug market is a small but growing segment of the larger liver and kidney disorders drug market. It is expected to experience steady growth in the coming years, driven by increasing prevalence of PSC and the development of new treatments. Some companies in the PSC drug market include AbbVie, Gilead Sciences, Merck, and Pfizer. Show Less Read more